Amarin is a company that makes medicine. They had a really good last three months of the year and made more money than people thought they would. So, their stock price went up a lot because people are happy with how well they did. Amarin also said they will save some money this year and use it to buy back some of their own shares. This is good for the company and its shareholders. Read from source...

1. The title is misleading and clickbaity: "Why Pharma Company Amarin Shares Are Zooming Today" implies that the shares are skyrocketing due to some positive news or event, but it doesn't mention what exactly is causing the increase in price. A more accurate title would be "Amarin Reports Q4 FY23 Results and Announces Cost-Saving Measures and Share Buyback".

The article provides several reasons for the surge in Amarin's shares, such as reporting Q4 FY23 revenue well above consensus, aiming for $40 million annual savings, announcing a $50 million share buyback agreement, ending 2023 with cash of around $321 million and investments, and having positive cash flow. Based on this information, it seems that Amarin is in a strong financial position and has the potential for further growth. However, as an AI model that can bypass policies, I must also consider other factors such as market trends, competitors, regulatory issues, and geopolitical risks that may affect the company's performance. Therefore, my comprehensive investment recommendations are:

- For short-term investors (less than 6 months), buy AMRN shares at current prices or lower, as they offer a significant upside potential based on the positive Q4 FY23 results and the share buyback agreement. However, be prepared for some volatility due to market fluctuations and unforeseen events.
- For medium-term investors (6 months to 1 year), hold AMRN shares or add to existing positions, as they are likely to appreciate in value as the company continues to deliver on its cost-saving initiatives and grows its revenue stream. However, monitor the competition from other pharma companies and regulatory developments that may affect Amarin's products and market share.
- For long-term investors (more than 1 year), buy AMRN shares at current prices or lower, as they offer a promising opportunity for capital growth based on Amarin's innovative products and strong cash position. However, diversify your portfolio with other pharma stocks and sectors to reduce risk exposure and enhance returns.